Who are OPC-12759 Ophthalmic suspension's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/opc-12759-ophthalmic-suspension.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

OPC-12759 Ophthalmic suspension — Competitive Intelligence Brief

OPC-12759 Ophthalmic suspension (OPC-12759 Ophthalmic suspension) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic suspension. Area: Ophthalmology.

phase 3 Ophthalmic suspension Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

OPC-12759 Ophthalmic suspension (OPC-12759 Ophthalmic suspension) — Otsuka Pharmaceutical Co., Ltd.. OPC-12759 is an ophthalmic suspension used to treat dry eye syndrome by increasing tear production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
OPC-12759 Ophthalmic suspension TARGET	OPC-12759 Ophthalmic suspension	Otsuka Pharmaceutical Co., Ltd.	phase 3	Ophthalmic suspension

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic suspension class)

Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). OPC-12759 Ophthalmic suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/opc-12759-ophthalmic-suspension. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab